DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Alendronate (Alendronate Sodium) - Published Studies

 
 



Alendronate Related Published Studies

Well-designed clinical trials related to Alendronate

Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. [2013]

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. [2012]

Prevention of Glucocorticoid-Induced Osteoporosis in Immunobullous Diseases With Alendronate: A Randomized, Double-blind, Placebo-Controlled Study. [2011.11.21]

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. [2011.10]

Effect of alendronate and vitamin D on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. [2011.08]

A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. [2011.07.06]

Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02. [2011.06]

Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. [2011.06]

Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. [2011.06]

"Clinical Efficacy Of 1% Alendronate Gel in Adjunct to Mechanotherapy in the Treatment of Aggressive Periodontitis - A Randomized Controlled Clinical Trial" [2011.05.24]

"Clinical Efficacy of 1% Alendronate Gel as Local Drug Delivery System in the Treatment of Chronic Periodontitis - A Randomized Controlled Clinical Trial" [2011.05.04]

Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. [2011.04]

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. [2011.03.03]

Longitudinal evaluation of the effects of alendronate on MRI bone microarchitecture in postmenopausal osteopenic women. [2011.03.01]

Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency. [2011.03]

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. [2011.02]

An open-label trial comparing alendronate and alphacalcidol in reducing falls and hip fractures in disabled stroke patients. [2011.01]

The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate. [2011.01]

The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis. [2011]

A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. [2010.12]

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. [2010.10]

Alendronate reduces osteoclast precursors in osteoporosis. [2010.10]

Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis. [2010.09]

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. [2010.08]

The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study. [2010.08]

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. [2010.08]

Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. [2010.07]

High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. [2010.05]

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. [2010.05]

The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. [2010.05]

Alendronate improves QOL of postmenopausal women with osteoporosis. [2010.04.26]

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. [2010.04]

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010.04]

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. [2010.01]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010.01]

Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). [2010.01]

Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. [2010]

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. [2010]

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. [2010]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010]

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. [2009.11]

Alendronate therapy in men with primary hyperparathyroidism. [2009.11]

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. [2009.10]

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. [2009.08.31]

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. [2009.08]

Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. [2009.08]

Vitamin D insufficiency does not affect response of bone mineral density to alendronate. [2009.07]

[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women] [2009.06.16]

A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. [2009.06]

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. [2009.06]

Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. [2009.05]

Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2009.05]

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]

Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009.04]

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. [2009.02.15]

Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. [2009.02]

Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. [2009.02]

Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. [2009.01]

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2009.01]

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. [2009]

Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]

Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women. [2009]

Two-way crossover bioequivalence study of alendronate sodium tablets in healthy, non-smoking male volunteers under fasted conditions. [2009]

Truncated area under the urinary excretion rate curve in the evaluation of alendronate bioequivalence after a single dose in healthy volunteers. [2009]

Alendronate is effective to treat bone loss in renal transplantation recipients. [2008.12]

A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. [2008.12]

Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]

Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. [2008.12]

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. [2008.11]

Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. [2008.11]

Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). [2008.10]

The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. [2008.10]

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [2008.09.20]

[Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] [2008.07.15]

The effects of systemic alendronate with or without intraalveolar collagen sponges on postextractive bone resorption: a single masked randomized clinical trial. [2008.07]

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. [2008.07]

Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. [2008.06.20]

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. [2008.04]

Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]

Alendronate decreases TRACP 5b activity in osteoarthritic bone. [2008.01.23]

Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. [2008.01]

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. [2008]

Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K(2) in postmenopausal women. [2008]

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. [2008]

Well-designed clinical trials possibly related to Alendronate

[Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2012]

Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. [2011.11.02]

[Frontiers in Vitamin D ; Basic Research and Clinical Application. Effect of active vitamin D(3) on osteoporosis]. [2011.11]

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. [2011.10]

The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. [2011.08]

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. [2011.06]

The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. [2011.04]

[Clinical observation on acupuncture for treatment of male osteoporosis]. [2011.01]

Increasing kyphosis predicts worsening mobility in older community-dwelling women: a prospective cohort study. [2011.01]

Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis. [2011.01]

Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). [2011.01]

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. [2011]

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. [2011]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014